Endologix Acquires Pounce System in Strategic Vascular Play

SANTA ROSA, CA – May 19, 2026 – Endologix LLC, a global medical device company focused on vascular disease, has finalized its acquisition of the Pounce™ Thrombectomy System from Surmodics, Inc., in a move that significantly broadens its therapeutic arsenal for peripheral vascular disease. The deal, which closed on May 18, brings a highly differentiated, FDA-cleared mechanical thrombectomy platform into the Endologix fold, promising to enhance treatment options for physicians and patients grappling with arterial blockages.

The acquisition marks a deliberate expansion for Endologix, a company already established in the vascular space with its DETOUR®, ALTO™, and AFX®2 platforms for treating conditions from abdominal aortic aneurysms to peripheral arterial disease. By integrating the Pounce system, Endologix strengthens its ability to offer a more comprehensive suite of tools to the vascular specialists who are its core customer base.

A Strategic Deepening of the Vascular Portfolio

The purchase of the Pounce system is more than a simple product line extension; it represents a calculated strategic maneuver to consolidate Endologix's position as a leader in vascular intervention. Wholly owned by the healthcare-focused investment firm Deerfield Management, Endologix has the backing to pursue growth through targeted acquisitions that align with its mission of addressing unmet clinical needs. This acquisition fits that model perfectly.

The Pounce system is designed to serve the same interventionalists who already rely on Endologix's other technologies. This synergy allows the company to leverage its existing commercial channels and relationships, offering physicians a more robust toolkit from a single, trusted partner. The integration of a core group of Surmodics team members who supported Pounce underscores Endologix's commitment to not just acquiring a product, but also the expertise behind it, ensuring a seamless transition and continued innovation.

"The Pounce Thrombectomy System is a strong strategic and clinical fit for Endologix," said John Liddicoat, M.D., President and Chief Executive Officer of Endologix, in a statement accompanying the announcement. "It serves the same physicians and patients we already work with every day and brings a clinically differentiated mechanical approach that complements our vascular intervention portfolio. We are excited to welcome members of the Pounce team as part of our intentional investment in innovation that helps vascular specialists deliver better care."

The Clinical Advantage of a Mechanical Approach

At the heart of the acquisition's significance is the Pounce system's innovative technology. It is a fully mechanical thrombectomy device designed to remove thrombi and emboli—the clots that block blood flow in peripheral arteries—without relying on thrombolytics (clot-busting drugs) or aspiration (suction).

This 'grab-and-go' solution is built around a proprietary dual-basket technology and a nitinol collection funnel. During a procedure, a physician guides the device to the clot, deploys the baskets to dislodge and capture the thrombus, and then withdraws it into the funnel for removal. This purely mechanical action offers several key advantages. It eliminates the systemic bleeding risks and need for post-procedure ICU monitoring often associated with thrombolytic drugs, making it a safer option for a broader range of patients. Furthermore, it avoids the significant blood loss that can occur with aspiration-based systems.

Impressive clinical data supports the system's efficacy. Interim results from the PROWL registry, a real-world study, demonstrated a 91.7% procedural success rate across 160 patients with a low incidence of device-related major adverse events. Critically, the study showed the device was effective in removing not only fresh, soft clots but also the subacute and chronic, organized thrombus that other methods struggle to clear. This capability significantly expands the treatment window for patients with acute and chronic limb ischemia.

Dr. Venkatesh Ramaiah, Chief of Vascular and Endovascular Surgery at Pulse Cardiovascular Institute, commented on the clinical synergy. “I have used both Pounce and Endologix technologies in my practice, and bringing these solutions together under one organization makes a great deal of clinical sense," he stated. "The Pounce fully mechanical thrombectomy system offers a grab-and-go solution that does not rely on thrombolytics or aspiration and complements Endologix’s portfolio of vascular technologies for the treatment of peripheral arterial disease."

Reshaping a Competitive Thrombectomy Landscape

The peripheral thrombectomy market is a dynamic and competitive space, with the mechanical device segment projected to hold the largest market share, reaching an estimated 37.2% in 2026. The Pounce system enters this arena with distinct advantages over established technologies.

Unlike aspiration-based platforms such as Penumbra's Indigo® System, Pounce mechanically grabs and contains the clot, which physicians have found to be particularly effective for more organized thrombus. It also differs from pharmacomechanical devices like Boston Scientific's AngioJet™, which uses high-pressure saline jets in conjunction with lytics. The Pounce system's independence from capital equipment further lowers the barrier to adoption for hospitals and clinics.

Its versatility is another key differentiator. The platform includes three commercially available configurations that cater to a wide spectrum of arterial anatomy. The Pounce LP (Low Profile) is designed for smaller vessels (2-4 mm) found below the knee, the standard Pounce addresses mid-sized arteries (3.5-6 mm), and the Pounce XL is built for larger vessels like the iliac and femoral arteries (5.5-10 mm). This comprehensive range allows physicians to treat blockages from the thigh down to the foot with a single, familiar platform, enhancing procedural efficiency.

The ability to effectively treat a wide array of clot morphologies and vessel sizes with a single-session, purely mechanical device positions the Pounce system as a formidable player, capable of capturing significant market share by offering a simpler, safer, and often more effective solution for complex peripheral arterial blockages.